Provided by Tiger Trade Technology Pte. Ltd.

CALIDI BIOTHERAPEUTICS INC

1.31
-0.0500-3.68%
Post-market: 1.27-0.0400-3.05%19:52 EDT
Volume:32.40K
Turnover:42.80K
Market Cap:3.39M
PE:-0.04
High:1.34
Open:1.31
Low:1.30
Close:1.36
52wk High:27.84
52wk Low:1.25
Shares:2.58M
Float Shares:2.56M
Volume Ratio:1.03
T/O Rate:1.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-33.3374
EPS(LYR):-95.1334
ROE:-672.22%
ROA:-134.79%
PB:1.08
PE(LYR):-0.01

Loading ...

Calidi presents preclinical data for RedTail-derived CLD-401, targets IND filing end-2026

Reuters
·
Apr 20

Calidi Biotherapeutics publishes RedTail virotherapy platform presentation

Reuters
·
Apr 20

Calidi Biotherapeutics announces annual shareholder meeting via webcast

Reuters
·
Apr 18

Calidi Biotherapeutics to present RedTail platform data at oncolytic virus conference

Reuters
·
Apr 14

Calidi Biotherapeutics to present RedTail systemic virotherapy data at ASGCT meeting

Reuters
·
Apr 08

Calidi Biotherapeutics director Allan Camaisa to leave board at annual meeting

Reuters
·
Apr 03

Calidi Biotherapeutics to present new CLD-401 preclinical data at AACR meeting

Reuters
·
Apr 02

Calidi Biotherapeutics to present AACR data on RedTail TROP-2 T-cell engager candidate

Reuters
·
Apr 01

Calidi Biotherapeutics FY2025 loss per share narrows 83.33% to $5.95; revenue falls 41.67% to $50,000

Reuters
·
Mar 28

Calidi Biotherapeutics Inc: Q4 Net Loss per Share $0.57

THOMSON REUTERS
·
Mar 28

Press Release: Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights

Dow Jones
·
Mar 28

BRIEF-Calidi Biotherapeutics Announces Partnership With Avance Clinical To Facilitate Australian Regulatory Approval

Reuters
·
Mar 24

Calidi Biotherapeutics Announces Partnership With Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of Cld-401 Clinical Trials

THOMSON REUTERS
·
Mar 24

Calidi Biotherapeutics partners with Avance Clinical on CLD-401 trial launch in Australia

Reuters
·
Mar 24